LACK OF EFFECT OF CHRONIC DEVELOPMENTAL LEAD TREATMENT ON BIOGENIC-AMINES AND METABOLITES IN MONKEY CEREBROSPINAL-FLUID

被引:0
作者
FERGUSON, SA
KRAEMER, GW
BOWMAN, RE
SCHMIDT, DE
EBERT, MH
机构
[1] UNIV WISCONSIN,HARLOW PRIMATE LAB,MADISON,WI 53715
[2] UNIV WISCONSIN,WISCONSIN REG PRIMATE RES CTR,MADISON,WI 53715
[3] UNIV WISCONSIN,WISCONSIN PSYCHIAT RES INST,MADISON,WI 53715
[4] VANDERBILT UNIV,MED CTR,SCH MED,DEPT PSYCHIAT,NASHVILLE,TN 37232
关键词
LEAD; CEREBROSPINAL FLUID; MONKEY;
D O I
10.1016/0892-0362(93)90003-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Concentrations of 3,4 dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), norepinephrine (NE), 3-methoxy-4-hydroxyphenylglycol (MHPG), and 5-hydroxyindoleacetic acid (5-HIAA) were assayed in the cerebrospinal fluid (CSF) of control and chronically lead-treated nursery-reared rhesus monkeys sampled periodically from infancy through adulthood. Blood lead levels peaked at 62 mug/dl at 1.5 months of age, averaged 45 mug/dl for the remainder of the first year postpartum, and were maintained at 14 mug/dl from 20-58 months of age. Cisternal CSF samples were collected monthly from 5-35 months of age and every. 1-4 months from 36-58 months of age. Biogenic amine and metabolite concentrations were assayed by high-performance liquid chromatography with electrochemical detection. Overall concentrations of DOPAC, HVA, NE, MHPG, and 5-HIAA were not significantly different in the control and lead-treated groups nor were there any significant interactions between lead treatment and age for any measure. DOPAC, HVA, and 5-HIAA concentrations decreased gradually with age, whereas MHPG concentration decreased-sharply between 35 and 40 months of age. NE concentration remained stable across development.
引用
收藏
页码:229 / 235
页数:7
相关论文
共 42 条
[1]   FUNCTIONAL DEVELOPMENT OF DORSOLATERAL PREFRONTAL CORTEX - ANALYSIS UTILIZING REVERSIBLE CRYOGENIC DEPRESSION [J].
ALEXANDER, GE ;
GOLDMAN, PS .
BRAIN RESEARCH, 1978, 143 (02) :233-249
[2]  
ALEXANDER GE, 1980, NEUROSCI RES PROG B, V20, P471
[3]   EFFECTS OF HALOPERIDOL AND PROBENECID ON PLASMA AND CSF DOPAMINE METABOLITES IN RHESUS-MONKEY (MACACCA-MULATTA) [J].
BACOPOULOS, NG ;
HENINGER, GR ;
ROTH, RH .
LIFE SCIENCES, 1978, 23 (17-1) :1805-1812
[4]   SEROTONIN AND DOPAMINE METABOLITES IN BRAIN-REGIONS AND CEREBROSPINAL-FLUID OF A PRIMATE SPECIES - EFFECTS OF KETAMINE AND FLUPHENAZINE [J].
BACOPOULOS, NG ;
REDMOND, DE ;
ROTH, RH .
JOURNAL OF NEUROCHEMISTRY, 1979, 32 (04) :1215-1218
[5]   ONTOGENY OF CATECHOLAMINE AND GABA LEVELS IN RAT-BRAIN - LACK OF EFFECT OF PERINATAL LEAD-EXPOSURE [J].
BAILEY, CC ;
KITCHEN, I .
TOXICOLOGY LETTERS, 1986, 30 (01) :97-102
[6]  
BHATTACHARYA A, 1988, NEUROTOXICOLOGY, V9, P327
[7]  
BLOMQUIST A. J., 1961, PROC ANIMAL CARE PANEL, V11, P57
[8]   RETENTION OF DELAYED-ALTERNATION - EFFECT OF SELECTIVE LESIONS OF SULCUS PRINCIPALIS [J].
BUTTERS, N ;
PANDYA, D .
SCIENCE, 1969, 165 (3899) :1271-&
[9]   PLASMA, URINE, AND CSF CATECHOLAMINE CONCENTRATIONS DURING AND AFTER KETAMINE ANESTHESIA [J].
CHERNOW, B ;
LAKE, CR ;
CRUESS, D ;
COYLE, J ;
HUGHES, P ;
BALESTRIERI, F ;
CASEY, L ;
RAINEY, TG ;
FLETCHER, JR .
CRITICAL CARE MEDICINE, 1982, 10 (09) :600-603
[10]   LOW-LEVEL LEAD-EXPOSURE INCREASES SENSITIVITY TO THE STIMULUS PROPERTIES OF DOPAMINE-D1 AND DOPAMINE-D2 AGONISTS [J].
CORYSLECHTA, DA ;
WIDZOWSKI, DV .
BRAIN RESEARCH, 1991, 553 (01) :65-74